European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) study group, I. E., Collins, J., Judd, A., Gibb, D., Thorne, C., Bailey, H., & Goodall, R. (2018). Time to switch to second-line antiretroviral therapy in children with HIV in Europe and Thailand. Clinical Infectious Diseases. doi:10.1093/cid/cix854

Mocumbi, S., Gafos, M., Munguambe, K., Goodall, R., & McCormack, S. (2017). High HIV prevalence and incidence among women in Southern Mozambique: Evidence from the MDP microbicide feasibility study. PLoS ONE, 12 (3). doi:10.1371/journal.pone.0173243

Dolling, D. I., Goodall, R. L., Chirara, M., Hakim, J., Nkurunziza, P., Munderi, P., . . . DART Virology Group. (2017). The virological durability of first-line ART among HIV-positive adult patients in resource limited settings without virological monitoring: a retrospective analysis of DART trial data. BMC Infectious Diseases, 17 (1), 160. doi:10.1186/s12879-017-2266-3

Once vs. twice-daily lopinavir/ritonavir in HIV-1-infected children. (2015). AIDS, 29 (18), 2447-2457. doi:10.1097/QAD.0000000000000862

Gupta, R. K., Goodall, R. L., Ranopa, M., Kityo, C., Munderi, P., Lyagoba, F., . . . DART Virology Group and Trial Team. (2014). High Rate of HIV Re-suppression After Viral Failure on First Line Antiretroviral Therapy in the Absence of Switch to Second Line. Clin Infect Dis, 58 (7), 1023-1026. doi:10.1093/cid/cit933

Crichton, S., Jesson, J., Aké-Assi, M. -. H., Belfrage, E., Davies, M. -. A., Pinto, J., . . . Goodall, R. (2023). Global variations in pubertal growth spurts in adolescents living with perinatal HIV. AIDS. doi:10.1097/QAD.0000000000003602

Hughes, G., Bern, H., Chiang, C. Y., Goodall, R. L., Nunn, A. J., Rusen, I. D., & Meredith, S. K. (2022). ECG monitoring in STREAM Stage 1: can we identify those at increased risk of QT prolongation?. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 26 (11), 1065-1070. doi:10.5588/ijtld.22.0063

Rosu, L., Madan, J. J., Tomeny, E. M., Muniyandi, M., Nidoi, J., Girma, M., . . . STREAM, S. H. E. E. C. (2022). Economic evaluation of shortened, bedaquiline-containing treatment regimens for rifampicin-resistant tuberculosis (STREAM stage 2): a within-trial analysis of a randomised controlled trial. The Lancet Global Health. doi:10.1016/S2214-109X(22)00498-3

Goodall, R. L., Meredith, S. K., Nunn, A. J., Bayissa, A., Bhatnagar, A. K., Bronson, G., . . . STREAM study collaborators. (2022). Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial. The Lancet. doi:10.1016/S0140-6736(22)02078-5

Kokebu, D. M., Ahmed, S., Moodliar, R., Chiang, C. -. Y., Torrea, G., Van Deun, A., . . . Nunn, A. J. (2022). Failure or relapse predictors for the STREAM Stage 1 short regimen for RR-TB. International Journal of Tuberculosis and Lung Disease, 26 (8), 753-759. doi:10.5588/ijtld.22.0073